PMID- 10958254
OWN - NLM
STAT- MEDLINE
DCOM- 20000915
LR  - 20170214
IS  - 0269-8811 (Print)
IS  - 0269-8811 (Linking)
VI  - 12
IP  - 3
DP  - 1998
TI  - A randomized, double-blind, parallel-group comparison of venlafaxine and 
      clomipramine in outpatients with major depression.
PG  - 273-8
AB  - A multicentre, randomized, double-blind study was conducted to compare the safety 
      and antidepressant efficacy of venlafaxine and clomipramine in 102 outpatients 
      with major depression. The patients received either venlafaxine or clomipramine 
      at a dose titrated from 50 mg to a maximum of 150 mg/day during the first 2 weeks 
      of treatment. Treatment was continued for up to 43 days. Montgomery Asberg 
      Depression Rating Scale (MADRS) and Hamilton Depression Rating Scale (HAM-D) 
      scores decreased significantly (p < or = 0.05) from baseline in each treatment 
      group but were not significantly different between groups. Response rates on the 
      MADRS and HAM-D were 62% and 59%, respectively, with venlafaxine and 54% and 43%, 
      respectively, with clomipramine. Treatment-emergent study events were the primary 
      reason for withdrawal in only 13% of venlafaxine-treated patients and 20% of 
      clomipramine-treated patients. On questionnaires, the incidence of 
      anticholinergic-type events was 60% with venlafaxine and 68% with clomipramine. 
      However, significantly (p = 0.043) more patients in the clomipramine group 
      reported multiple anticholinergic events than in the venlafaxine group. In the 
      clomipramine group, mean ventricular heart rate increased significantly (p = 
      0.003) and mean systolic blood pressure decreased significantly (p = 0.028) from 
      baseline, but no clinically significant electrocardiographic changes were 
      observed. These results confirm the efficacy and safety of venlafaxine in the 
      treatment of outpatients suffering from major depression.
FAU - Samuelian, J C
AU  - Samuelian JC
AD  - CHU Timone, Marseille, France.
FAU - Hackett, D
AU  - Hackett D
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Psychopharmacol
JT  - Journal of psychopharmacology (Oxford, England)
JID - 8907828
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 0 (Antidepressive Agents, Tricyclic)
RN  - 0 (Cyclohexanols)
RN  - 7D7RX5A8MO (Venlafaxine Hydrochloride)
RN  - NUV44L116D (Clomipramine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antidepressive Agents, Second-Generation/adverse effects/*therapeutic use
MH  - Antidepressive Agents, Tricyclic/adverse effects/*therapeutic use
MH  - Clomipramine/adverse effects/*therapeutic use
MH  - Cyclohexanols/adverse effects/*therapeutic use
MH  - Depressive Disorder/*drug therapy/psychology
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Psychiatric Status Rating Scales
MH  - Venlafaxine Hydrochloride
EDAT- 2000/08/25 11:00
MHDA- 2000/09/23 11:01
CRDT- 2000/08/25 11:00
PHST- 2000/08/25 11:00 [pubmed]
PHST- 2000/09/23 11:01 [medline]
PHST- 2000/08/25 11:00 [entrez]
AID - 10.1177/026988119801200307 [doi]
PST - ppublish
SO  - J Psychopharmacol. 1998;12(3):273-8. doi: 10.1177/026988119801200307.